{"gene":"HSD17B11","run_date":"2026-04-28T18:06:53","timeline":{"discoveries":[{"year":2003,"finding":"HSD17B11 (17β-HSDXI) converts 5α-androstane-3α,17β-diol to androsterone, establishing its enzymatic activity in androgen metabolism; cAMP down-regulates its enzymatic activity and gene expression in mouse Y1 cells; the enzyme localizes to steroidogenic cells (syncytiotrophoblasts, Leydig cells, granulosa cells, sebaceous gland) and adrenal cortex; a polymorphic poly-A stretch in the 5' UTR modulates enzyme expression levels; the promoter contains steroidogenic factor-1 half-sites.","method":"Enzymatic activity assays in transfected cells, immunohistochemistry, Northern blot, promoter sequence analysis, cAMP regulation experiments in mouse Y1 cells","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1-2 — direct enzymatic activity assay with defined substrate/product, localization by IHC with functional context, replicated across multiple tissue types","pmids":["12697717"],"is_preprint":false},{"year":1998,"finding":"HSD17B11 (Pan1b) acts as a dehydrogenase on 17β-hydroxysteroids and does not metabolize glucocorticoids, establishing its substrate class specificity and distinguishing it from 11β-HSD family members.","method":"Expression in CHO cells (CHOP) with substrate metabolism assays","journal":"Endocrine research","confidence":"Medium","confidence_rationale":"Tier 2 — direct enzymatic activity assay in transfected cells, but single lab and confounded by endogenous oxidoreductase activity","pmids":["9888557"],"is_preprint":false},{"year":2011,"finding":"HSD17B11 transcription in prostate cancer cells is regulated by transcription factors Sp1 and C/EBPα, which are directly recruited to the HSD17B11 proximal promoter region (-107/+18); mutagenesis of Sp1 and C/EBP binding sites abolishes promoter activity.","method":"Transfection/reporter assays, mutagenesis, DAPA (DNA affinity precipitation assay), ChIP assay","journal":"Molecular and cellular endocrinology","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis combined with ChIP confirmation of direct promoter binding, moderate evidence","pmids":["21549806"],"is_preprint":false},{"year":2010,"finding":"HSD17B11 expression in HepG2 hepatocarcinoma cells is induced by ectopic expression of C/EBPα or C/EBPβ, but this induction is not mediated through the CCAAT boxes in the proximal promoter region.","method":"Ectopic expression of C/EBP isoforms, gene reporter assays, promoter mutagenesis","journal":"The Journal of steroid biochemistry and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 — reporter assays plus mutagenesis, single lab","pmids":["20638476"],"is_preprint":false},{"year":2018,"finding":"HSD17B11 (estradiol 17β-dehydrogenase 11) localizes to lipid droplets (LDs) in adrenal cells, as confirmed by proteomics of adrenal LD fractions and Western blot subcellular fractionation; LDs from adrenal glands have capacity for steroid hormone metabolism.","method":"LD proteomics (human, macaque, rodent adrenal glands), Western blot fractionation, subcellular localization","journal":"Proteomics","confidence":"Medium","confidence_rationale":"Tier 2 — proteomics plus Western blot validation of LD localization, moderate evidence","pmids":["30358111"],"is_preprint":false},{"year":2022,"finding":"HSD17B11, as a short-chain dehydrogenase/reductase (SDR), bioactivates terminal alkynylcarbinols (including dialkynylcarbinols) by oxidizing the carbinol center to generate dialkynylketones, which are highly protein-reactive electrophiles that covalently modify proteins involved in protein-quality control (via Michael addition on cysteines and lysines), causing ER stress, unfolded protein response activation, ubiquitin-proteasome system inhibition, and apoptosis.","method":"Genetic screen in haploid human cells, in vitro enzymatic assay, mass spectrometry characterization of adducts, cell death/ER stress assays, clickable probe confirmation","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1 — genetic screen identified HSD17B11, enzymatic mechanism characterized biochemically, mechanism validated by multiple orthogonal approaches in one study","pmids":["35535493"],"is_preprint":false},{"year":2023,"finding":"HSD17B11 SDR enzymatic activity bioactivates phenyl-dialkynylcarbinols (PACs) in an enantiospecific manner to generate reactive ynones that covalently modify cellular proteins, causing ER stress, UPS inhibition, and apoptosis; docking to HSD17B11 AlphaFold model provided structural basis for substrate selectivity versus its paralogue HSD17B13.","method":"Clickable probe experiments, cell cytotoxicity assays with HSD17B11-expressing cells, molecular docking to AlphaFold model, PAC prodrug design with selectivity profiling","journal":"Journal of medicinal chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — functional prodrug bioactivation confirmed in cells, structural insight from computational model only","pmids":["37816126"],"is_preprint":false},{"year":2020,"finding":"CRISPR-Cas9 genome-wide knockout screen identified HSD17B11 as a mediator of the selective cytotoxic effects of dehydrofalcarinol (a polyacetylene alkynylcarbinol) in mesenchymal stem-like triple-negative breast cancer MDA-MB-231 cells that express high levels of this protein.","method":"CRISPR-Cas9 genome-wide knockout screen, cancer dependency database (Project Achilles) analysis","journal":"Journal of natural products","confidence":"Medium","confidence_rationale":"Tier 2 — genome-wide CRISPR screen identified functional dependency, confirmed by cancer dependency data","pmids":["33021790"],"is_preprint":false},{"year":2022,"finding":"FTO (m6A demethylase) promotes HSD17B11 expression in esophageal cancer cells by reducing m6A modification on HSD17B11 mRNA; depleting YTHDF1 (m6A reader) increases HSD17B11 protein levels, indicating that FTO acts through YTHDF1 to affect HSD17B11 translation; increased HSD17B11 promotes lipid droplet formation in esophageal cancer cells.","method":"meRIP-seq, transcriptome analysis, FTO knockdown/overexpression, YTHDF1 depletion, lipid droplet formation assay","journal":"Cell & bioscience","confidence":"Medium","confidence_rationale":"Tier 2 — meRIP-seq plus functional validation in cancer cells, single lab","pmids":["35568876"],"is_preprint":false},{"year":2024,"finding":"HSD17B11 was identified as an interaction partner of GCKIII kinases (MST3, STK25, MST4) in human hepatocytes via yeast two-hybrid screen; HSD17B11 controls GCKIII kinase action via a conformational change, placing it in the pathway regulating hepatocellular lipid homeostasis.","method":"Genome-wide yeast two-hybrid screen of human hepatocyte library, functional lipid content assays in hepatocytes","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 3 — yeast two-hybrid interaction identification with functional context, conformational change mechanism not directly demonstrated biochemically","pmids":["39395791"],"is_preprint":false},{"year":2019,"finding":"Knockdown of HSD17B11 mRNA in goat IVF embryos significantly decreased the developmental rate, establishing a required role for HSD17B11 in early embryonic development during embryonic genome activation.","method":"RNA knockdown in IVF goat embryos, developmental rate quantification","journal":"Reproduction (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function in embryos with defined developmental phenotype, but goat ortholog and single study","pmids":["30407918"],"is_preprint":false}],"current_model":"HSD17B11 is a short-chain dehydrogenase/reductase (SDR) localized to the endoplasmic reticulum and lipid droplets of steroidogenic cells that catalyzes the oxidation of 5α-androstane-3α,17β-diol to androsterone (androgen inactivation), bioactivates alkynylcarbinol prodrugs into protein-reactive electrophiles causing ER stress and apoptosis, promotes lipid droplet formation downstream of FTO/m6A regulation, interacts with GCKIII kinases to regulate hepatocellular lipid homeostasis, and is transcriptionally controlled by Sp1 and C/EBP family members."},"narrative":{"teleology":[{"year":1998,"claim":"Establishing that HSD17B11 (Pan1b) possesses dehydrogenase activity toward 17β-hydroxysteroids but not glucocorticoids resolved its substrate class specificity and distinguished it from the 11β-HSD family.","evidence":"Substrate metabolism assays in CHO cells expressing recombinant protein","pmids":["9888557"],"confidence":"Medium","gaps":["Endogenous oxidoreductase activity in CHO cells could confound substrate specificity determination","Preferred physiological substrate not defined","Kinetic parameters not reported"]},{"year":2003,"claim":"Identification of the specific reaction — oxidation of 5α-androstane-3α,17β-diol to androsterone — and localization to steroidogenic cells (Leydig, granulosa, syncytiotrophoblast, adrenal cortex) established HSD17B11 as an androgen-inactivating enzyme in reproductive and endocrine tissues.","evidence":"Enzymatic activity assays in transfected cells, immunohistochemistry across multiple tissues, Northern blot, cAMP regulation in mouse Y1 adrenal cells","pmids":["12697717"],"confidence":"High","gaps":["Crystal structure not available to explain substrate selectivity","Relevance of the 5′ UTR poly-A polymorphism to disease phenotypes unknown","In vivo contribution to circulating androgen levels not tested"]},{"year":2010,"claim":"Demonstrating that C/EBPα and C/EBPβ induce HSD17B11 expression — but not through the proximal CCAAT boxes — revealed indirect or distal transcriptional regulation, complemented in 2011 by showing that Sp1 and C/EBPα directly bind and activate the proximal promoter in prostate cancer cells.","evidence":"Reporter assays, promoter mutagenesis, DAPA, ChIP in prostate cancer cells (2011); ectopic C/EBP expression in HepG2 cells (2010)","pmids":["20638476","21549806"],"confidence":"High","gaps":["Chromatin context and epigenetic regulation of the HSD17B11 locus not explored","Whether Sp1/C/EBP regulation operates in non-cancerous steroidogenic tissues is untested"]},{"year":2018,"claim":"Proteomic identification of HSD17B11 on adrenal lipid droplets established a second subcellular compartment (beyond ER) where steroid-metabolizing SDR activity resides.","evidence":"LD proteomics from human, macaque, and rodent adrenal glands with Western blot fractionation validation","pmids":["30358111"],"confidence":"Medium","gaps":["Whether LD-localized HSD17B11 is enzymatically active on steroids at the droplet surface is not demonstrated","Targeting signal directing HSD17B11 to LDs not identified"]},{"year":2019,"claim":"Knockdown of HSD17B11 in goat IVF embryos decreased developmental rates, revealing a non-steroidogenic role during embryonic genome activation.","evidence":"RNA knockdown in goat IVF embryos with developmental rate quantification","pmids":["30407918"],"confidence":"Medium","gaps":["Mechanism by which HSD17B11 supports embryonic development is unknown","Not confirmed in mammalian species other than goat","Whether the effect is steroid-dependent or lipid-metabolism-dependent is unclear"]},{"year":2020,"claim":"A genome-wide CRISPR screen identified HSD17B11 as required for the selective cytotoxicity of the alkynylcarbinol dehydrofalcarinol, linking its SDR activity to xenobiotic bioactivation for the first time.","evidence":"CRISPR-Cas9 knockout screen in MDA-MB-231 triple-negative breast cancer cells","pmids":["33021790"],"confidence":"Medium","gaps":["Enzymatic mechanism of bioactivation not yet characterized at this point","Whether other SDR family members contribute to alkynylcarbinol metabolism not addressed"]},{"year":2022,"claim":"Biochemical characterization showed HSD17B11 oxidizes alkynylcarbinols to protein-reactive electrophilic ketones that covalently modify proteostasis machinery (via Michael addition on Cys/Lys residues), causing ER stress, UPR activation, proteasome inhibition, and apoptosis — defining a complete prodrug bioactivation mechanism.","evidence":"In vitro enzymatic assay, mass spectrometry of protein adducts, clickable probes, ER stress and cell death assays in haploid human cells","pmids":["35535493"],"confidence":"High","gaps":["No co-crystal structure of HSD17B11 with alkynylcarbinol substrate","Full spectrum of covalently modified protein targets not catalogued","In vivo bioactivation pharmacokinetics not established"]},{"year":2022,"claim":"Discovery that FTO demethylates m6A on HSD17B11 mRNA to increase its expression — with YTHDF1 acting as a negative translational regulator — and that elevated HSD17B11 drives lipid droplet formation established an epitranscriptomic–lipid metabolism axis in esophageal cancer.","evidence":"meRIP-seq, FTO knockdown/overexpression, YTHDF1 depletion, and lipid droplet quantification in esophageal cancer cells","pmids":["35568876"],"confidence":"Medium","gaps":["Whether the lipid droplet phenotype requires HSD17B11 enzymatic activity or a non-catalytic scaffolding role is unknown","Single cancer cell line study; generalizability to normal tissues untested"]},{"year":2023,"claim":"Enantiospecific bioactivation of phenyl-dialkynylcarbinols by HSD17B11 and molecular docking to its AlphaFold model provided a structural rationale for substrate selectivity over its paralogue HSD17B13.","evidence":"Clickable probe experiments, cytotoxicity assays, molecular docking to AlphaFold-predicted structure","pmids":["37816126"],"confidence":"Medium","gaps":["Structural model is computational (AlphaFold), not experimentally determined","Selectivity determinants not validated by site-directed mutagenesis"]},{"year":2024,"claim":"Identification of GCKIII kinases (MST3, STK25, MST4) as HSD17B11 interaction partners in hepatocytes placed HSD17B11 in a kinase-regulatory circuit controlling lipid homeostasis, expanding its role beyond steroid metabolism.","evidence":"Genome-wide yeast two-hybrid screen of human hepatocyte library with functional lipid content assays","pmids":["39395791"],"confidence":"Medium","gaps":["Interaction not confirmed by reciprocal co-immunoprecipitation or in vivo methods","Conformational change mechanism claimed but not biochemically demonstrated","Direct vs. indirect effect on hepatocellular lipid content not resolved"]},{"year":null,"claim":"The in vivo physiological significance of HSD17B11 in androgen metabolism, lipid homeostasis, and embryonic development remains unresolved, as no knockout animal model or human genetic disease association has been reported.","evidence":"","pmids":[],"confidence":"Low","gaps":["No animal knockout phenotype reported","No human Mendelian disease linked to HSD17B11 mutations","Relative contribution of HSD17B11 versus other 17β-HSDs to systemic androgen inactivation unknown","Experimental crystal structure unavailable"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,1,5,6]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[5,6]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[5]},{"term_id":"GO:0005811","term_label":"lipid droplet","supporting_discovery_ids":[4,8]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,4,8,9]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[5,6]}],"complexes":[],"partners":["MST3","STK25","MST4","FTO","YTHDF1","SP1","CEBPA"],"other_free_text":[]},"mechanistic_narrative":"HSD17B11 is a short-chain dehydrogenase/reductase (SDR) that functions in androgen inactivation, lipid droplet biology, and xenobiotic bioactivation. It catalyzes the NAD⁺-dependent oxidation of 5α-androstane-3α,17β-diol to androsterone and acts on 17β-hydroxysteroids but not glucocorticoids, localizing to the endoplasmic reticulum and lipid droplets of steroidogenic tissues including adrenal cortex, Leydig cells, and syncytiotrophoblasts [PMID:12697717, PMID:9888557, PMID:30358111]. HSD17B11 also bioactivates alkynylcarbinol prodrugs by oxidizing their carbinol center to generate protein-reactive electrophilic ketones that covalently modify proteostasis machinery, triggering ER stress, unfolded protein response activation, and apoptosis [PMID:35535493, PMID:37816126]. Beyond steroid metabolism, HSD17B11 promotes lipid droplet formation downstream of FTO/m6A-mediated mRNA regulation in cancer cells and interacts with GCKIII kinases (MST3, STK25, MST4) to regulate hepatocellular lipid homeostasis [PMID:35568876, PMID:39395791]."},"prefetch_data":{"uniprot":{"accession":"Q8NBQ5","full_name":"Estradiol 17-beta-dehydrogenase 11","aliases":["17-beta-hydroxysteroid dehydrogenase 11","17-beta-HSD 11","17bHSD11","17betaHSD11","17-beta-hydroxysteroid dehydrogenase XI","17-beta-HSD XI","17betaHSDXI","Cutaneous T-cell lymphoma-associated antigen HD-CL-03","CTCL-associated antigen HD-CL-03","Dehydrogenase/reductase SDR family member 8","Retinal short-chain dehydrogenase/reductase 2","retSDR2","Short chain dehydrogenase/reductase family 16C member 2"],"length_aa":300,"mass_kda":33.0,"function":"Can convert androstan-3-alpha,17-beta-diol (3-alpha-diol) to androsterone in vitro, suggesting that it may participate in androgen metabolism during steroidogenesis. May act by metabolizing compounds that stimulate steroid synthesis and/or by generating metabolites that inhibit it. Has no activity toward DHEA (dehydroepiandrosterone), or A-dione (4-androste-3,17-dione), and only a slight activity toward testosterone to A-dione. Tumor-associated antigen in cutaneous T-cell lymphoma","subcellular_location":"Endoplasmic reticulum; Lipid droplet","url":"https://www.uniprot.org/uniprotkb/Q8NBQ5/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HSD17B11","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"COPA","stoichiometry":0.2},{"gene":"COPB2","stoichiometry":0.2},{"gene":"COPE","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/HSD17B11","total_profiled":1310},"omim":[{"mim_id":"612831","title":"17-@BETA-HYDROXYSTEROID DEHYDROGENASE XI; HSD17B11","url":"https://www.omim.org/entry/612831"},{"mim_id":"612127","title":"17-@BETA-HYDROXYSTEROID DEHYDROGENASE XIII; HSD17B13","url":"https://www.omim.org/entry/612127"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Lipid droplets","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"intestine","ntpm":271.8},{"tissue":"liver","ntpm":225.9}],"url":"https://www.proteinatlas.org/search/HSD17B11"},"hgnc":{"alias_symbol":["RetSDR2","17-BETA-HSD11","17-BETA-HSDXI","PAN1B","SDR16C2"],"prev_symbol":["DHRS8"]},"alphafold":{"accession":"Q8NBQ5","domains":[{"cath_id":"3.40.50.720","chopping":"34-286","consensus_level":"high","plddt":94.7187,"start":34,"end":286}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8NBQ5","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8NBQ5-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8NBQ5-F1-predicted_aligned_error_v6.png","plddt_mean":93.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HSD17B11","jax_strain_url":"https://www.jax.org/strain/search?query=HSD17B11"},"sequence":{"accession":"Q8NBQ5","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8NBQ5.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8NBQ5/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8NBQ5"}},"corpus_meta":[{"pmid":"12697717","id":"PMC_12697717","title":"17 beta-hydroxysteroid dehydrogenase type XI localizes to human steroidogenic cells.","date":"2003","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12697717","citation_count":59,"is_preprint":false},{"pmid":"35568876","id":"PMC_35568876","title":"m6A demethylase FTO promotes tumor progression via regulation of lipid metabolism in esophageal cancer.","date":"2022","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/35568876","citation_count":55,"is_preprint":false},{"pmid":"9888557","id":"PMC_9888557","title":"Cloning and expression of a novel tissue specific 17beta-hydroxysteroid dehydrogenase.","date":"1998","source":"Endocrine research","url":"https://pubmed.ncbi.nlm.nih.gov/9888557","citation_count":31,"is_preprint":false},{"pmid":"30358111","id":"PMC_30358111","title":"The Adrenal Lipid Droplet is a New Site for Steroid Hormone Metabolism.","date":"2018","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/30358111","citation_count":23,"is_preprint":false},{"pmid":"32595704","id":"PMC_32595704","title":"Lnc-HSD17B11-1:1 Functions as a Competing Endogenous RNA to Promote Colorectal Cancer Progression by Sponging miR-338-3p to Upregulate MACC1.","date":"2020","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32595704","citation_count":20,"is_preprint":false},{"pmid":"20638476","id":"PMC_20638476","title":"Type 10 17β-hydroxysteroid dehydrogenase expression is regulated by C/EBPβ in HepG2 cells.","date":"2010","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20638476","citation_count":14,"is_preprint":false},{"pmid":"36135372","id":"PMC_36135372","title":"Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment.","date":"2022","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/36135372","citation_count":13,"is_preprint":false},{"pmid":"33021790","id":"PMC_33021790","title":"CRISPR-Cas9 Genome-Wide Knockout Screen Identifies Mechanism of Selective Activity of Dehydrofalcarinol in Mesenchymal Stem-like Triple-Negative Breast Cancer Cells.","date":"2020","source":"Journal of natural products","url":"https://pubmed.ncbi.nlm.nih.gov/33021790","citation_count":13,"is_preprint":false},{"pmid":"30407918","id":"PMC_30407918","title":"Identification and characterization of ERV transcripts in goat embryos.","date":"2019","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/30407918","citation_count":11,"is_preprint":false},{"pmid":"37511041","id":"PMC_37511041","title":"Epigenomics Analysis of the Suppression Role of SIRT1 via H3K9 Deacetylation in Preadipocyte Differentiation.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37511041","citation_count":11,"is_preprint":false},{"pmid":"19469652","id":"PMC_19469652","title":"17beta-hydroxysteroid dehydrogenase type 11 (Pan1b) expression in human prostate cancer.","date":"2009","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/19469652","citation_count":10,"is_preprint":false},{"pmid":"37086619","id":"PMC_37086619","title":"G0S2 promotes antiestrogenic and pro-migratory responses in ER+ and ER- breast cancer cells.","date":"2023","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37086619","citation_count":8,"is_preprint":false},{"pmid":"21549806","id":"PMC_21549806","title":"Transcriptional regulation of type 11 17β-hydroxysteroid dehydrogenase expression in prostate cancer cells.","date":"2011","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21549806","citation_count":7,"is_preprint":false},{"pmid":"35535493","id":"PMC_35535493","title":"SDR enzymes oxidize specific lipidic alkynylcarbinols into cytotoxic protein-reactive species.","date":"2022","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/35535493","citation_count":5,"is_preprint":false},{"pmid":"37816126","id":"PMC_37816126","title":"Phenyl dialkynylcarbinols, a Bioinspired Series of Synthetic Antitumor Acetylenic Lipids.","date":"2023","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37816126","citation_count":5,"is_preprint":false},{"pmid":"26472732","id":"PMC_26472732","title":"Human dehydrogenase/reductase (SDR family) member 8 (DHRS8): a description and evaluation of its biochemical properties.","date":"2015","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26472732","citation_count":4,"is_preprint":false},{"pmid":"39395791","id":"PMC_39395791","title":"GCKIII kinases control hepatocellular lipid homeostasis via shared mode of action.","date":"2024","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/39395791","citation_count":4,"is_preprint":false},{"pmid":"35690242","id":"PMC_35690242","title":"Differential proteomics analysis of JEG-3 and JAR placental cell models and the effect of androgen treatment.","date":"2022","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/35690242","citation_count":3,"is_preprint":false},{"pmid":"37782778","id":"PMC_37782778","title":"Identification of ferroptotic genes and phenotypes in idiopathic nonobstructive azoospermia.","date":"2023","source":"Systems biology in reproductive medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37782778","citation_count":2,"is_preprint":false},{"pmid":"41407026","id":"PMC_41407026","title":"Decipher the molecular network of PFOA in inflammatory bowel disease through integrating machine learning, molecular docking strategies, and validation in vitro.","date":"2025","source":"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association","url":"https://pubmed.ncbi.nlm.nih.gov/41407026","citation_count":0,"is_preprint":false},{"pmid":"40299520","id":"PMC_40299520","title":"Exploring Immune-Related Ferroptosis Genes in Thyroid Cancer: A Comprehensive Analysis.","date":"2025","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/40299520","citation_count":0,"is_preprint":false},{"pmid":"41541230","id":"PMC_41541230","title":"A comprehensive analysis of the correlation between plasma cytokines/chemokines and tumor immune microenvironment signature influences the response of checkpoint inhibitors in advanced non-small-cell lung cancer.","date":"2026","source":"Clinical & translational immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41541230","citation_count":0,"is_preprint":false},{"pmid":"41029168","id":"PMC_41029168","title":"Exploring therapeutic targets for hepatocellular carcinoma through druggable genes.","date":"2025","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41029168","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":14153,"output_tokens":2639,"usd":0.041022},"stage2":{"model":"claude-opus-4-6","input_tokens":6017,"output_tokens":2845,"usd":0.151815},"total_usd":0.192837,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"HSD17B11 (17β-HSDXI) converts 5α-androstane-3α,17β-diol to androsterone, establishing its enzymatic activity in androgen metabolism; cAMP down-regulates its enzymatic activity and gene expression in mouse Y1 cells; the enzyme localizes to steroidogenic cells (syncytiotrophoblasts, Leydig cells, granulosa cells, sebaceous gland) and adrenal cortex; a polymorphic poly-A stretch in the 5' UTR modulates enzyme expression levels; the promoter contains steroidogenic factor-1 half-sites.\",\n      \"method\": \"Enzymatic activity assays in transfected cells, immunohistochemistry, Northern blot, promoter sequence analysis, cAMP regulation experiments in mouse Y1 cells\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct enzymatic activity assay with defined substrate/product, localization by IHC with functional context, replicated across multiple tissue types\",\n      \"pmids\": [\"12697717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"HSD17B11 (Pan1b) acts as a dehydrogenase on 17β-hydroxysteroids and does not metabolize glucocorticoids, establishing its substrate class specificity and distinguishing it from 11β-HSD family members.\",\n      \"method\": \"Expression in CHO cells (CHOP) with substrate metabolism assays\",\n      \"journal\": \"Endocrine research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct enzymatic activity assay in transfected cells, but single lab and confounded by endogenous oxidoreductase activity\",\n      \"pmids\": [\"9888557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HSD17B11 transcription in prostate cancer cells is regulated by transcription factors Sp1 and C/EBPα, which are directly recruited to the HSD17B11 proximal promoter region (-107/+18); mutagenesis of Sp1 and C/EBP binding sites abolishes promoter activity.\",\n      \"method\": \"Transfection/reporter assays, mutagenesis, DAPA (DNA affinity precipitation assay), ChIP assay\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis combined with ChIP confirmation of direct promoter binding, moderate evidence\",\n      \"pmids\": [\"21549806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"HSD17B11 expression in HepG2 hepatocarcinoma cells is induced by ectopic expression of C/EBPα or C/EBPβ, but this induction is not mediated through the CCAAT boxes in the proximal promoter region.\",\n      \"method\": \"Ectopic expression of C/EBP isoforms, gene reporter assays, promoter mutagenesis\",\n      \"journal\": \"The Journal of steroid biochemistry and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assays plus mutagenesis, single lab\",\n      \"pmids\": [\"20638476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HSD17B11 (estradiol 17β-dehydrogenase 11) localizes to lipid droplets (LDs) in adrenal cells, as confirmed by proteomics of adrenal LD fractions and Western blot subcellular fractionation; LDs from adrenal glands have capacity for steroid hormone metabolism.\",\n      \"method\": \"LD proteomics (human, macaque, rodent adrenal glands), Western blot fractionation, subcellular localization\",\n      \"journal\": \"Proteomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — proteomics plus Western blot validation of LD localization, moderate evidence\",\n      \"pmids\": [\"30358111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HSD17B11, as a short-chain dehydrogenase/reductase (SDR), bioactivates terminal alkynylcarbinols (including dialkynylcarbinols) by oxidizing the carbinol center to generate dialkynylketones, which are highly protein-reactive electrophiles that covalently modify proteins involved in protein-quality control (via Michael addition on cysteines and lysines), causing ER stress, unfolded protein response activation, ubiquitin-proteasome system inhibition, and apoptosis.\",\n      \"method\": \"Genetic screen in haploid human cells, in vitro enzymatic assay, mass spectrometry characterization of adducts, cell death/ER stress assays, clickable probe confirmation\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — genetic screen identified HSD17B11, enzymatic mechanism characterized biochemically, mechanism validated by multiple orthogonal approaches in one study\",\n      \"pmids\": [\"35535493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HSD17B11 SDR enzymatic activity bioactivates phenyl-dialkynylcarbinols (PACs) in an enantiospecific manner to generate reactive ynones that covalently modify cellular proteins, causing ER stress, UPS inhibition, and apoptosis; docking to HSD17B11 AlphaFold model provided structural basis for substrate selectivity versus its paralogue HSD17B13.\",\n      \"method\": \"Clickable probe experiments, cell cytotoxicity assays with HSD17B11-expressing cells, molecular docking to AlphaFold model, PAC prodrug design with selectivity profiling\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional prodrug bioactivation confirmed in cells, structural insight from computational model only\",\n      \"pmids\": [\"37816126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CRISPR-Cas9 genome-wide knockout screen identified HSD17B11 as a mediator of the selective cytotoxic effects of dehydrofalcarinol (a polyacetylene alkynylcarbinol) in mesenchymal stem-like triple-negative breast cancer MDA-MB-231 cells that express high levels of this protein.\",\n      \"method\": \"CRISPR-Cas9 genome-wide knockout screen, cancer dependency database (Project Achilles) analysis\",\n      \"journal\": \"Journal of natural products\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide CRISPR screen identified functional dependency, confirmed by cancer dependency data\",\n      \"pmids\": [\"33021790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FTO (m6A demethylase) promotes HSD17B11 expression in esophageal cancer cells by reducing m6A modification on HSD17B11 mRNA; depleting YTHDF1 (m6A reader) increases HSD17B11 protein levels, indicating that FTO acts through YTHDF1 to affect HSD17B11 translation; increased HSD17B11 promotes lipid droplet formation in esophageal cancer cells.\",\n      \"method\": \"meRIP-seq, transcriptome analysis, FTO knockdown/overexpression, YTHDF1 depletion, lipid droplet formation assay\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — meRIP-seq plus functional validation in cancer cells, single lab\",\n      \"pmids\": [\"35568876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"HSD17B11 was identified as an interaction partner of GCKIII kinases (MST3, STK25, MST4) in human hepatocytes via yeast two-hybrid screen; HSD17B11 controls GCKIII kinase action via a conformational change, placing it in the pathway regulating hepatocellular lipid homeostasis.\",\n      \"method\": \"Genome-wide yeast two-hybrid screen of human hepatocyte library, functional lipid content assays in hepatocytes\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — yeast two-hybrid interaction identification with functional context, conformational change mechanism not directly demonstrated biochemically\",\n      \"pmids\": [\"39395791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Knockdown of HSD17B11 mRNA in goat IVF embryos significantly decreased the developmental rate, establishing a required role for HSD17B11 in early embryonic development during embryonic genome activation.\",\n      \"method\": \"RNA knockdown in IVF goat embryos, developmental rate quantification\",\n      \"journal\": \"Reproduction (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function in embryos with defined developmental phenotype, but goat ortholog and single study\",\n      \"pmids\": [\"30407918\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HSD17B11 is a short-chain dehydrogenase/reductase (SDR) localized to the endoplasmic reticulum and lipid droplets of steroidogenic cells that catalyzes the oxidation of 5α-androstane-3α,17β-diol to androsterone (androgen inactivation), bioactivates alkynylcarbinol prodrugs into protein-reactive electrophiles causing ER stress and apoptosis, promotes lipid droplet formation downstream of FTO/m6A regulation, interacts with GCKIII kinases to regulate hepatocellular lipid homeostasis, and is transcriptionally controlled by Sp1 and C/EBP family members.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"HSD17B11 is a short-chain dehydrogenase/reductase (SDR) that functions in androgen inactivation, lipid droplet biology, and xenobiotic bioactivation. It catalyzes the NAD⁺-dependent oxidation of 5α-androstane-3α,17β-diol to androsterone and acts on 17β-hydroxysteroids but not glucocorticoids, localizing to the endoplasmic reticulum and lipid droplets of steroidogenic tissues including adrenal cortex, Leydig cells, and syncytiotrophoblasts [PMID:12697717, PMID:9888557, PMID:30358111]. HSD17B11 also bioactivates alkynylcarbinol prodrugs by oxidizing their carbinol center to generate protein-reactive electrophilic ketones that covalently modify proteostasis machinery, triggering ER stress, unfolded protein response activation, and apoptosis [PMID:35535493, PMID:37816126]. Beyond steroid metabolism, HSD17B11 promotes lipid droplet formation downstream of FTO/m6A-mediated mRNA regulation in cancer cells and interacts with GCKIII kinases (MST3, STK25, MST4) to regulate hepatocellular lipid homeostasis [PMID:35568876, PMID:39395791].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Establishing that HSD17B11 (Pan1b) possesses dehydrogenase activity toward 17β-hydroxysteroids but not glucocorticoids resolved its substrate class specificity and distinguished it from the 11β-HSD family.\",\n      \"evidence\": \"Substrate metabolism assays in CHO cells expressing recombinant protein\",\n      \"pmids\": [\"9888557\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Endogenous oxidoreductase activity in CHO cells could confound substrate specificity determination\",\n        \"Preferred physiological substrate not defined\",\n        \"Kinetic parameters not reported\"\n      ]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identification of the specific reaction — oxidation of 5α-androstane-3α,17β-diol to androsterone — and localization to steroidogenic cells (Leydig, granulosa, syncytiotrophoblast, adrenal cortex) established HSD17B11 as an androgen-inactivating enzyme in reproductive and endocrine tissues.\",\n      \"evidence\": \"Enzymatic activity assays in transfected cells, immunohistochemistry across multiple tissues, Northern blot, cAMP regulation in mouse Y1 adrenal cells\",\n      \"pmids\": [\"12697717\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Crystal structure not available to explain substrate selectivity\",\n        \"Relevance of the 5′ UTR poly-A polymorphism to disease phenotypes unknown\",\n        \"In vivo contribution to circulating androgen levels not tested\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrating that C/EBPα and C/EBPβ induce HSD17B11 expression — but not through the proximal CCAAT boxes — revealed indirect or distal transcriptional regulation, complemented in 2011 by showing that Sp1 and C/EBPα directly bind and activate the proximal promoter in prostate cancer cells.\",\n      \"evidence\": \"Reporter assays, promoter mutagenesis, DAPA, ChIP in prostate cancer cells (2011); ectopic C/EBP expression in HepG2 cells (2010)\",\n      \"pmids\": [\"20638476\", \"21549806\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Chromatin context and epigenetic regulation of the HSD17B11 locus not explored\",\n        \"Whether Sp1/C/EBP regulation operates in non-cancerous steroidogenic tissues is untested\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Proteomic identification of HSD17B11 on adrenal lipid droplets established a second subcellular compartment (beyond ER) where steroid-metabolizing SDR activity resides.\",\n      \"evidence\": \"LD proteomics from human, macaque, and rodent adrenal glands with Western blot fractionation validation\",\n      \"pmids\": [\"30358111\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether LD-localized HSD17B11 is enzymatically active on steroids at the droplet surface is not demonstrated\",\n        \"Targeting signal directing HSD17B11 to LDs not identified\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Knockdown of HSD17B11 in goat IVF embryos decreased developmental rates, revealing a non-steroidogenic role during embryonic genome activation.\",\n      \"evidence\": \"RNA knockdown in goat IVF embryos with developmental rate quantification\",\n      \"pmids\": [\"30407918\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism by which HSD17B11 supports embryonic development is unknown\",\n        \"Not confirmed in mammalian species other than goat\",\n        \"Whether the effect is steroid-dependent or lipid-metabolism-dependent is unclear\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"A genome-wide CRISPR screen identified HSD17B11 as required for the selective cytotoxicity of the alkynylcarbinol dehydrofalcarinol, linking its SDR activity to xenobiotic bioactivation for the first time.\",\n      \"evidence\": \"CRISPR-Cas9 knockout screen in MDA-MB-231 triple-negative breast cancer cells\",\n      \"pmids\": [\"33021790\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Enzymatic mechanism of bioactivation not yet characterized at this point\",\n        \"Whether other SDR family members contribute to alkynylcarbinol metabolism not addressed\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Biochemical characterization showed HSD17B11 oxidizes alkynylcarbinols to protein-reactive electrophilic ketones that covalently modify proteostasis machinery (via Michael addition on Cys/Lys residues), causing ER stress, UPR activation, proteasome inhibition, and apoptosis — defining a complete prodrug bioactivation mechanism.\",\n      \"evidence\": \"In vitro enzymatic assay, mass spectrometry of protein adducts, clickable probes, ER stress and cell death assays in haploid human cells\",\n      \"pmids\": [\"35535493\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No co-crystal structure of HSD17B11 with alkynylcarbinol substrate\",\n        \"Full spectrum of covalently modified protein targets not catalogued\",\n        \"In vivo bioactivation pharmacokinetics not established\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Discovery that FTO demethylates m6A on HSD17B11 mRNA to increase its expression — with YTHDF1 acting as a negative translational regulator — and that elevated HSD17B11 drives lipid droplet formation established an epitranscriptomic–lipid metabolism axis in esophageal cancer.\",\n      \"evidence\": \"meRIP-seq, FTO knockdown/overexpression, YTHDF1 depletion, and lipid droplet quantification in esophageal cancer cells\",\n      \"pmids\": [\"35568876\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether the lipid droplet phenotype requires HSD17B11 enzymatic activity or a non-catalytic scaffolding role is unknown\",\n        \"Single cancer cell line study; generalizability to normal tissues untested\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Enantiospecific bioactivation of phenyl-dialkynylcarbinols by HSD17B11 and molecular docking to its AlphaFold model provided a structural rationale for substrate selectivity over its paralogue HSD17B13.\",\n      \"evidence\": \"Clickable probe experiments, cytotoxicity assays, molecular docking to AlphaFold-predicted structure\",\n      \"pmids\": [\"37816126\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Structural model is computational (AlphaFold), not experimentally determined\",\n        \"Selectivity determinants not validated by site-directed mutagenesis\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identification of GCKIII kinases (MST3, STK25, MST4) as HSD17B11 interaction partners in hepatocytes placed HSD17B11 in a kinase-regulatory circuit controlling lipid homeostasis, expanding its role beyond steroid metabolism.\",\n      \"evidence\": \"Genome-wide yeast two-hybrid screen of human hepatocyte library with functional lipid content assays\",\n      \"pmids\": [\"39395791\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Interaction not confirmed by reciprocal co-immunoprecipitation or in vivo methods\",\n        \"Conformational change mechanism claimed but not biochemically demonstrated\",\n        \"Direct vs. indirect effect on hepatocellular lipid content not resolved\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The in vivo physiological significance of HSD17B11 in androgen metabolism, lipid homeostasis, and embryonic development remains unresolved, as no knockout animal model or human genetic disease association has been reported.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No animal knockout phenotype reported\",\n        \"No human Mendelian disease linked to HSD17B11 mutations\",\n        \"Relative contribution of HSD17B11 versus other 17β-HSDs to systemic androgen inactivation unknown\",\n        \"Experimental crystal structure unavailable\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 5, 6]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [5, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0005811\", \"supporting_discovery_ids\": [4, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 4, 8, 9]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [5, 6]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"MST3\",\n      \"STK25\",\n      \"MST4\",\n      \"FTO\",\n      \"YTHDF1\",\n      \"SP1\",\n      \"CEBPA\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}